Dexmedetomidine, is a α 2 adrenergic agonist approved by the Food and Drug administration for sedation and analgesia. A highly potent α2 adrenergic agonist, it has quick onset of action, with peak effects within 1 hour of administration. It is metabolized in the liver and eliminated in the urine as a glucuronide. Dexmedetomidine is a substrate and inhibitor of cytochrome oxidase 2D6, but clinical evidence of significant drug interactions is lacking. Clinical trials suggest efficacy for the treatment of delirium in the intensive care unit setting with efficacy comparable to haloperidol and benzodiazepines. Dexmedetomidine also has an opioid-sparing action and can act to enhance analgesia. The purpose of this article is to review the pharmacodynamics and pharmacology of dexmedetomidine, and examine its potential use in the palliative care population, especially with regard to the management of delirium.
Savola JM, Virtanen R.Central [alpha] 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. Eur J Pharmacol. 1991;195(2):193-199.
7.
Lamont L.[alpha]2-Agonists. In: Gaynor JS, Muir WW III, eds. Handbook of Veterinary Pain Management. 2nd ed. Saint Louis, MO: Mosby; 2009:210-230.
8.
Panzer O., Moitra V., Sladen RNPharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists . Crit Care Clin.2009;25(3):451-469.
9.
Paris A., Tonner PHDexmedetomidine in anaesthesia. Curr Opin Anesthesiol . 2005;18(4):412-418.
10.
Shannon R., Chaudhry M.Effect of 1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006;152(5):842-850.
11.
Maze M., Scarfini C., Cavaliere F.New agents for sedation in the intensive care unit. Crit Care Clin. 2001;17(4):881-898.
12.
Nelson LE, Lu J., Guo T., Saper CB, Franks NP, Maze M.The [alpha] 2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology . 2003;98(2):428-436.
13.
Kable JW, Murrin LC, Bylund DB In vivo gene modification elucidates subtype-specific functions of alpha 2-adrenergic receptors. J Pharmacol Exp Ther. 2000;293(1):1-7.
14.
Niddam R., Angel I., Bidet S., Langer SZPharmacological characterization of alpha-2 adrenergic receptor subtype involved in the release of insulin from isolated rat pancreatic islets. J Pharmacol Exp Ther. 1990;254(3):883-887.
15.
Takada K., Clark DJ, Davies MF, et al. Meperidine exerts agonist activity at the [alpha] 2B-adrenoceptor subtype. Anesthesiology. 2002;96(6):1420-1426.
16.
De Sarro GB , Ascioti C., Froio F., Libri V., Nistico G.Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1-and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol. 1987;90(4):675-685.
17.
Lehtimäki J., Leino T., Koivisto A., et al. In vitro and in vivo profiling of fadolmidine, a novel potent [alpha] 2-adrenoceptor agonist with local mode of action. Eur J Pharmacol. 2008; 599(1-3):65-71.
18.
Khan ZP, Ferguson CN, Jones RMAlpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 2002;54(2):146-165.
19.
Reis DJ, Regunathan S., Golanov EV, Feinstein DLProtection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective . Am J Cardiol. 1994;74(13):A25-A30.
20.
McKay BE , Lado WE, Martin LJ, Galic MA, Fournier NMLearning and memory in agmatine-treated rats . Pharmacol Biochem Behav . 2002;72(3):551-557.
21.
Bricca G., Greney H., Zhang J., et al. Human brain imidazoline receptors: further characterization with [3H] clonidine. Eur J Pharmacol. 1994 ;266(1):25-33.
22.
Sullivan AF , Kalso EA, McQuay HJ, Dickenson AHThe antinociceptive actions of dexmedetomidine on dorsal horn neuronal responses in the anaesthetized rat. Eur J Pharmacol. 1992; 215(1):127-133.
23.
Takizuka A. , Minami K., Uezono Y., et al. Dexmedetomidine inhibits muscarinic type 3 receptors expressed in Xenopus oocytes and muscarine-induced intracellular Ca 2+ elevation in cultured rat dorsal root ganglia cells. Naunyn Schmiedebergs Arch Pharmacol. 2007;375(5):293-301.
24.
Nazarian A. , Christianson CA, Hua XY, Yaksh TLDexmedetomidine and ST-91 analgesia in the formalin model is mediated by 2A-adrenoceptors: a mechanism of action distinct from morphine. Br J Pharmacol . 2008;155(7):1117-1126.
25.
Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GLThe alpha 2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha 2 agonists and is necessary for spinal adrenergic-opioid synergy . J Neurosci. 1997;17(18):7157-7165.
26.
Wang XM, Zhang ZJ, Bains R., Mokha SSEffect of antisense knock-down of [alpha] 2a-and [alpha] 2c-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002;98(1-2):27-35.
27.
Poree LR, Guo TZ, Kingery WS, Maze M.The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors. Anesth Analg. 1998; 87(4):941-948.
28.
Green GM, Lyons L., Dickenson AH[alpha] 2-Adrenoceptor antagonists enhance responses of dorsal horn neurones to formalin induced inflammation. Eur J Pharmacol . 1998;347(2-3):201-204.
29.
Ramsay E., Michael A., Luterman DLDexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004;101(3): 787-790.
30.
Kalso EA, Pöyhiä R., Rosenberg PHSpinal antinociception by dexmedetomidine, a highly selective 2-adrenergic agonist. Pharmacol Toxicol.2009;68(2):140-143.
31.
Guneli E., Yavasoglu K., Ulkn N., Apaydin S., Uyar M., Uyar M.Analysis of the antinociceptive effect of systemic administration of tramadol and dexmedetomidine combination on rat models of acute and neuropathic pain . Pharmacol Biochem Behav. 2007;88(1):9-17.
32.
Tham SM, Angus JA, Tudor EM, Wright CESynergistic and additive interactions of the cannabinoid agonist CP55, 940 with opioid receptor and 2-adrenoceptor agonists in acute pain models in mice . Br J Pharmacol. 2005;144(6):875-884.
33.
Ulger F., Bozkurt A., Bilge SS, et al. The antinociceptive effects of intravenous dexmedetomidine in colorectal distension-induced visceral pain in rats: the role of opioid receptors . Anesth Analg.2009;109(2):616-622.
34.
Cortinez LI , Hsu YW, Sum-Ping ST, et al. Dexmedetomidine pharmacodynamics: Part II: Crossover comparison of the analgesic effect of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology . 2004;101(5):1077-1083.
35.
Angst MS, Ramaswamy B., Davies MF, Maze M.Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology . 2004;101(3):744-752.
36.
Boyer J.Treating agitation with dexmedetomidine in the ICU. Dimens Crit Care Nurs.2009;28(3):102-109.
37.
Carollo DS, Nossaman BD, Ramadhyani U.Dexmedetomidine: a review of clinical applications. Curr Opin Anesthesiol. 2008; 21(4):457-461.
38.
Tobias JDSubcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children. J Opioid Manag. 2008 ;4(4):187-191.
39.
Kivistö KT, Kallio A., Neuvonen PJPharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. Eur J Clin Pharmacol. 1994 ;46(4):345-349.
40.
Anttila M., Penttilä J., Helminen A., Vuorilehto L., Scheinin H.Bioavailability of dexmedetomidine after extravascular doses in healthy subjects . Br J Clin Pharmacol. 2003;56(6):691-693.
41.
Product information. Precedex (dexmedetomidine) . Lake Forest, IL: Hospira; April 2004.
42.
Vilo S., Rautiainen P., Kaisti K., et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth. 2008;100(5):697-700.
43.
Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LHY.A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105(2):374-380.
44.
Scheinin H. , Karhuvaara S., Olkkola KT, et al. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol Therap. 1992;52(5):537-546.
45.
Rodrigues AD , Roberts EMThe in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos. 1997;25(5):651-655.
46.
Karol MD, Maze M.Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans . Best Pract Res Clin Anaesthesiol. 2000;14(2):261-269.
47.
DeWolfAM ,Fragen RJ,Avram MJ,Fitzgerald PC,Rahimi-Danesh F.The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 2001;93(5):1205-1209.
48.
Shah AN, Koneru J., Nicoara A., Goldfeder LB, Thomas K., Ehlert FADexmedetomidine related cardiac arrest in a patient with permanent pacemaker; a cautionary tale. Pacing Clin Electrophysiol. 2008;30(9):1158-1160.
49.
Muntazar M. , Kumar FCCardiac arrest, a preventable yet a possible risk of dexmedetomidine: fact or fiction? Anesthesiology . 2004;101(6):1478-1479.
50.
Jalowiecki P., Rudner R., Gonciarz M., Kawecki P., Petelenz M., Dziurdzik P.Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology . 2005;103(2):269-273.
51.
Gerlach AT, Dasta JFDexmedetomidine: an updated review. Ann Pharmacother . 2007;41(2):245-252.
52.
Mukhtar AM, Obayah EM, Hassona AMThe use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg. 2006;103(1): 52-56.
53.
Gerlach AT, Dasta JF, Steinberg S., Martin LC, Cook CHA new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients. J Crit Care.2009;24(4):568-574.
54.
Jackson KC, Wohlt P., Fine PGDexmedetomidine. J Pain Palliative Care Pharmacother . 2006;20(2):23-27.
55.
Rahman West R., Rhodes A., Grounds RMThe Role of Dexmedetomidine in Intensive Care . Intensive Care Medicine. 2009; 906-914.
56.
Venn RM, Grounds RMComparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth . 2001;87(5):684-690.
57.
Reade MC, O’Sullivan K., Bates S., Goldsmith D., Ainslie WR, Bellomo R.Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009;13(3):R75.
58.
Riker RR, Shehabi Y., Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA.2009;301(5):489-499.
59.
Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653.
60.
Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJSedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699-705.
61.
Lin TF, Yeh YC, Lin FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth.2009;102(1):117-122.
62.
Wahlander S. , Frumento RJ, Wagener G., et al. A prospective, double-blind, randomized, placebo-controlled study of dexmedetomidine as an adjunct to epidural analgesia after thoracic surgery. J Cardiothorac Vasc Anesth. 2005;19(5):630-635.
63.
Al-Metwalli RR, Mowafi HA, Ismail SA, et al. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery . Br J Anaesth. 2008;101(3):395-399.
64.
Baddigam K. , Russo P., Russo JA, Tobias JDDexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients . J Intensive Care Med. 2005;20(2):118-123.
65.
Finkel JC, Elrefai A.The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesth Analg. 2004;98(6):1658-1659.
66.
Finkel JC, Johnson YJ, Quezado Z.The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med. 2005;33(9):2110-2112.
67.
Maccioli GADexmedetomidine to facilitate drug withdrawal . Anesthesiology. 2003;98(2):575-577.
68.
Venn R., Newman P., Grounds R.A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003;29(2):201-207.
69.
Shehabi Y., Ruettimann U., Adamson H., Innes R., Ickeringill M.Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188-2196.
70.
Grant SA, Breslin DS, MacLeod DB, Gleason D., Martin G.Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases* 1. J Clin Anesth. 2004;16(2):124-126.
